Last reviewed · How we verify
Amphotericin B liposome for injection
Interferes with fungal cell membrane function
Interferes with fungal cell membrane function Used for Fungal infections.
At a glance
| Generic name | Amphotericin B liposome for injection |
|---|---|
| Also known as | the test product |
| Sponsor | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. |
| Drug class | Polyene antifungal |
| Target | Ergosterol |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
Amphotericin B binds to ergosterol in the fungal cell membrane, leading to cell lysis and death.
Approved indications
- Fungal infections
Common side effects
- Renal impairment
- Hypokalemia
- Anaphylaxis
Key clinical trials
- Human Bioequivalence Study of Liposomal Amphotericin B for Injection (NA)
- Platform Trial For Cryptococcal Meningitis (PHASE2, PHASE3)
- Human Bioequivalence Study of Amphotericin B Liposome for Injection (NA)
- Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients (NA)
- Study of the Clinical Benefits of Different Formulations of Amphotericin B
- Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis (NA)
- Bioequivalence of Amphotericin B Liposome for Injection (PHASE1)
- Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: